| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
PhiKan-083 Hydrochloride manufacturers
- PhiKan 083
-
- $38.00
-
2026-08-08
- CAS:880813-36-5
- Purity: 98.37%
- Supply Ability: 10g
|
| | PhiKan-083 Hydrochloride Basic information |
| | PhiKan-083 Hydrochloride Chemical Properties |
| Boiling point | 401.0±27.0 °C(Predicted) | | density | 1.09±0.1 g/cm3(Predicted) | | storage temp. | Store at 4°C | | solubility | <13.74mg/ml in H2O; <27.48mg/ml in DMSO | | form | solid | | pka | 9.71±0.10(Predicted) | | color | White |
| | PhiKan-083 Hydrochloride Usage And Synthesis |
| Uses | PhiKan-083 is a p53 stabilizing agent. PhiKan-083 preferentially binds mutated (Y220C) p53 over wild-type p53 at a site distinct from functional DNA/protein interaction regions. PhiKan-083 slows rate of thermal denaturation of p53-Y220C. | | Biological Activity | ki: ≈ 150 mphikan 083 is a critical p53 stabilizing agent by bonding its mutation y220cthe mutation y220c of p53 exists a surface cavity that destabilizes the protein by 4 kcal/mol, at a site that is not functional. a p53 stabilizing agent binding it is able to slow rate of thermal denaturation [1]. | | in vitro | isothermal titration of phikan083 with t-p53c-y220c exhibited 1:1 stoichiometry and a kd of 125 ± 10 m. phikan083 stabilized t-p53c-y220c in a concentration-dependent manner. in a simple binding model for phikan083 (t-p53c-y220c at 310 k (37°c)), in the absence of ligand, the protein gave a half-life of 3.8 min, while it increased to 15.7 min at saturating concentrations of phikan083. this is a proposed anticancer drug that could be developed for the y220c mutant using p53 stabilizing agent. the site of mutation in the oncogenic y220c mutant phikan083 binds with reasonable affinity is a druggable target. interestingly, the site of mutation does not exist in a region of the protein that is functionally important, it will be an excellent target for drug stabilization therapy. this suggests the crystal structure of the complex will be a fresh start for further rounds of drug design and refinement [1]. | | references | [1] boeckler fm, joerger ac, jaggi g, rutherford tj, veprintsev db, fersht ar. targeted rescue of a destabilized mutant of p53 by an in silico screened drug. proc natl acad sci u s a. 2008 jul 29; 105(30):10360-5. |
| | PhiKan-083 Hydrochloride Preparation Products And Raw materials |
|